cdmo.directory
← Compare landing

Dipharma vs Grifols Partnership

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/dipharma/grifols

CategoryDipharmaGrifols Partnership
Listed sitecdmocdmo
SummaryGlobal CDMO and API manufacturer with 600 employees, 4 cGMP plants, and 75+ years of experience in hazardous chemical synthesis, offering exclusive synthesis services and catalogue APIs with FDA, AIFA, and PMDA inspections since 1970.CDMO specializing in small molecule injectable products, including concentrated and diluted parenteral formulations and intravenous solutions, leveraging 100+ years of Grifols expertise.
Services
  • API Synthesis & Manufacturing
  • Process Development
  • CMC Analytical Development
  • Technology Transfer
  • CMC Regulatory Submission Support
  • Quality Control Testing
  • Formulation Development
  • Technology Transfer
  • CMC Regulatory Submission Support
  • API Synthesis & Manufacturing
  • Sterile Fill-Finish & Aseptic Manufacturing
  • Vial Filling
  • Process Development
  • Small Molecule Development & Manufacturing
  • Quality Control Testing
  • CMC Analytical Development
Modalities
  • Small Molecule
  • Biologics (Other)
  • Small Molecule
IndicationsData not yet provided.
  • Immunology
  • Neurology
  • Cardiovascular
  • Infectious Disease
  • Respiratory
Locations
  • Headquarters, Milan, Lombardy, Italy
  • Commercial Office, United States
  • Commercial Office, China
  • Headquarters, Sant Cugat del Vallès, Catalonia, Spain
CertificationsData not yet provided.Data not yet provided.
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.